Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio‐marker of fibroproliferative disease?
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The CCN (c yr61, c tgf, n ov) family of modular proteins regulate diverse biological affects including cell adhesion, matrix production, tissue remodelling, proliferation and differentiation. Recent targeted gene disruption studies have demonstrated the CCN family to be developmentally essential for chondrogenesis, osteogenesis and angiogenesis. CCN2 is induced by agents such as angiotensin II, endothelin‐1, glucocorticoids, HGF, TGFβ, and VEGF, and by hypoxia and biomechanical and shear stress. Dysregulated expression of CCN2 has also been widely documented in many fibroproliferative diseases. This mini‐review will focus on CCN2, and the recent progress in understanding CCN2 gene regulation in health and disease. That CCN2 should be considered a novel and informative surrogate clinical bio‐marker for fibroproliferative disease is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradham, D. M., Igarashi, A., Potter, R. L., & Grotendorst, G. R. (1991) · The Journal of cell biology · doi:10.1083/jcb.114.6.1285 · Cited by 880 · cited 2×
“CCN2 was initially identified as a protein secreted by cultured human endothelial cells ( Bradham et al. 1991 ).”
BackgroundConnective tissue growth factor: a mediator of TGF-β action on fibroblasts
Grotendorst, G. R. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00010-5 · Cited by 761 · cited 2×
“…Canada e-mail: Andrew.leask@schulich.uwo.ca X. Shi-wen :D. J. Abraham Centre for Rheumatology, Royal Free and University College Medical School, University College London (Royal Free Campus), Rowland Hill Street, London NW3 2PF, UK TGFβ in mesenchymal cells (Grotendorst 1997; Leask et al. 2004).”
BackgroundIgarashi, A., Okochi, H., Bradham, D. M., & Grotendorst, G. R. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.6.637 · Cited by 706 · cited 1×
“Although CCN2 is not normally expressed by other mesenchymal cells, it is rapidly induced during the tissue repair process, for example upon injury (Igarashi et al. 1993; Kapoor et al. 2008).”
BackgroundAll in the CCN family: essential matricellular signaling modulators emerge from the bunker
Leask, A., & Abraham, D. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.03270 · Cited by 655
Self-citationGrotendorst, G. R., Okochi, H., & Hayashi, N. (1996) · PubMed · Cited by 573
Expression of connective tissue growth factor in human renal fibrosis
Ito, Y., Aten, J., Bende, R. J., Oemar, B. S., Rabelink, T. J., Weening, J. J., & Goldschmeding, R. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00820.x · Cited by 562
CTGF and SMADs, Maintenance of Scleroderma Phenotype Is Independent of SMAD Signaling
Holmes, A., Abraham, D. J., Sa, S., Shiwen, X., Black, C. M., & Leask, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010149200 · Cited by 423 · cited 8×
“The BCE-1 site was originally thought to be involved with the TGFβ-induction of CCN2, but has subsequently been shown to be involved with basal promoter activity (Grotendorst et al. 1996; Leask et al. 2001; Holmes et al. 2001) and in response of the CCN2 promoter to ET-1, through ras/MEK/ERK signal transduction cascad…”
BackgroundInfluentialSelf-citationGene regulation of connective tissue growth factor: new targets for antifibrotic therapy?
Blom, I. E., Goldschmeding, R., & Leask, A. (2002) · Matrix Biology · doi:10.1016/s0945-053x(02)00055-0 · Cited by 338 · cited 2×
“CCN2 is over-expressed in connective tissue pathologies such as in excessive scarring and fibrosis and in stroma surrounding tumors (Blom et al. 2002).”
BackgroundSelf-citationExpression of connective tissue growth factor in experimental rat and human liver fibrosis
Paradis, V., Dargere, D., Vidaud, M., de Gouville, A.-C., Huet, S., Martinez, V., Gauthier, J.-M., Ba, N., Sobesky, R., Ratziu, V., et al. (1999) · Hepatology · doi:10.1002/hep.510300425 · Cited by 324 · cited 2×
“In adult mammals, CCN2 exhibits a restricted expression, produced only by hepatic stellate cells (Paradis et al. 1999; Chen et al. 2001) and kidney mesangial cells (Ito et al.”
BackgroundLuo, Q., Kang, Q., Si, W., Jiang, W., Park, J. K., Peng, Y., Li, X., Luu, H. H., Luo, J., Montag, A. G., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407810200 · Cited by 319 · cited 1×
“Finally, Wnt3a induces CCN2 through a β-catenin-dependent mechanism, although the promoter sequences mediating this action are unknown, they reside within in the first 805 base pairs of the CCN2 proximal promoter (Luo et al. 2004; Chen et al. 2007).”
BackgroundConnective Tissue Growth Factor Gene Regulation
Leask, A., Holmes, A., Black, C. M., & Abraham, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210366200 · Cited by 305
Self-citationHypoxic induction of Ctgf is directly mediated by Hif-1
Higgins, D. F., Biju, M. P., Akai, Y., Wutz, A., Johnson, R. S., & Haase, V. H. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00245.2004 · Cited by 282 · cited 2×
“The CCN2 proximal promoter is induced by a number of specific factors such as endothelin-1 (ET-1) and TGFβ in addition to changes such as hypoxia (Holmes et al. 2001; Leask et al. 2001, 2003; Shi-wen et al. 2004; Higgins et al. 2004).”
BackgroundAbraham, D. J., Shiwen, X., Black, C. M., Sa, S., Xu, Y., & Leask, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.15220 · Cited by 255
Self-citationThe Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
Kuiper, E. J., Van Nieuwenhoven, F. A., de Smet, M. D., van Meurs, J. C., Tanck, M. W., Oliver, N., Klaassen, I., Van Noorden, C. J. F., Goldschmeding, R., & Schlingemann, R. O. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002675 · Cited by 241 · cited 1×
“skin fibrosis in scleroderma (Dziadzio et al. 2005) Kidney allograft fibrosis (Cheng et al 2006) liver fibrosis (Gressner et al. 2006) chronic viral hepatitis (Gressner et al. 2006) Fibrotic carcinoid tumors (Kidd et al 2007) diabetic retinopathy ( Kuiper et al 2008 ) End-stage renal disease (Nguyen et al. 2006) myoca…”
BackgroundSato, S., Nagaoka, T., Hasegawa, M., Tamatani, T., Nakanishi, T., Takigawa, M., & Takehara, K. (2000) · PubMed · Cited by 233
Stratton, R., Shiwen, X., Martini, G., Holmes, A., Leask, A., Haberberger, T., Martin, G. R., Black, C. M., & Abraham, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12020 · Cited by 232 · cited 2×
“Moreover, prostaglandins [PGE(2)] and prostacyclins (such as the synthetic prostacyclin Iloprost) can antagonize CCN2 expression, including in scleroderma fibroblasts (Ricupero et al. 1999; Stratton et al. 2001, 2002 ).”
BackgroundSelf-citationCTGF expression in mesangial cells: Involvement of SMADs, MAP kinase, and PKC
Chen, Y., Blom, I. E., Sa, S., Goldschmeding, R., Abraham, D. J., & Leask, A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00567.x · Cited by 210
Self-citationA Polymorphism in the CTGF Promoter Region Associated with Systemic Sclerosis
Fonseca, C., Lindahl, G. E., Ponticos, M., Sestini, P., Renzoni, E. A., Holmes, A. M., Spagnolo, P., Pantelidis, P., Leoni, P., McHugh, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067655 · Cited by 201 · cited 2×
“derma patients which results in increased Sp1-dependent transcription (Fonseca et al. 2007).”
BackgroundSelf-citationEndothelin-1 Induces Expression of Matrix-associated Genes in Lung Fibroblasts through MEK/ERK
Shi-wen, X., Howat, S. L., Renzoni, E. A., Holmes, A., Pearson, J. D., Dashwood, M. R., Bou-Gharios, G., Denton, C. P., du Bois, R. M., Black, C. M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311430200 · Cited by 172 · cited 2×
“The CCN2 proximal promoter is induced by a number of specific factors such as endothelin-1 (ET-1) and TGFβ in addition to changes such as hypoxia (Holmes et al. 2001; Leask et al. 2001, 2003; Shi-wen et al. 2004; Higgins et al. 2004).”
BackgroundSelf-citationShi‐wen, X., Kennedy, L., Renzoni, E. A., Bou‐Gharios, G., du Bois, R. M., Black, C. M., Denton, C. P., Abraham, D. J., & Leask, A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23134 · Cited by 163
Self-citationNovel growth factors involved in the pathogenesis of proliferative vitreoretinopathy
Hinton, D. R., He, S., Jin, M., Barrón, E., & Ryan, S. J. (2002) · Eye · doi:10.1038/sj.eye.6700190 · Cited by 157 · cited 1×
“Similarly, NH2-terminal CCN2 is also increased in the vitreous of patients with active progressive diabetic proliferative vitreoretinopathy, suggesting that it represents a surrogate marker of fibrosis in the disorder (Hinton et al. 2002).”
BackgroundCCN2 Is Necessary for Adhesive Responses to Transforming Growth Factor-β1 in Embryonic Fibroblasts
Shi-wen, X., Stanton, L. A., Kennedy, L., Pala, D., Chen, Y., Howat, S. L., Renzoni, E. A., Carter, D. E., Bou-Gharios, G., Stratton, R. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511343200 · Cited by 150
Self-citationStratton, R., Rajkumar, V., Ponticos, M., Nichols, B., Shiwen, X., Black, C. M., Abraham, D. J., & Leask, A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0204fje · Cited by 143 · cited 3×
“Iloprost works, at least in part, by antagonizing MEK/ERK signaling (Stratton et al. 2002) and, indeed, the MEK inhibitor U0126 reduces CCN2 expression in response to TGFβ and ET-1 in fibroblasts as well as constitutive over-expression of CCN2 in the pancreatic cancer cell line PANC-1 (Pickles and…”
BackgroundSelf-citationLeask, A., Denton, C. P., & Abraham, D. J. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2003.22133.x · Cited by 138 · cited 8×
“The Smad element of the CCN2 promoter is not sufficient to confer TGFβ-responsiveness to a heterologous promoter (Leask et al. 2001), but rather acts in concert with a tandem repeat of an element similar to an Ets/TEF recognition motif (Leask et al. 2003).”
BackgroundInfluentialSelf-citationGressner, O. A., Lahme, B., Rehbein, K., Siluschek, M., Weiskirchen, R., & Gressner, A. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.029 · Cited by 133
Tamatani, T., Kobayashi, H., Tezuka, K., Sakamoto, S., Suzuki, K., Nakanishi, T., Takigawa, M., & Miyano, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9543 · Cited by 124 · cited 1×
“Hepatic fibrosis in biliary atresia (Tamatani et al. 1998)”
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts
Leask, A., Sa, S., Holmes, A. M., Shiwen, X., Black, C. M., & Abraham, D. (2001) · Molecular Pathology · doi:10.1136/mp.54.3.180 · Cited by 121 · cited 7×
“The Smad element of the CCN2 promoter is not sufficient to confer TGFβ-responsiveness to a heterologous promoter (Leask et al. 2001), but rather acts in concert with a tandem repeat of an element similar to an Ets/TEF recognition motif (Leask et al. 2003).”
BackgroundInfluentialSelf-citationShiwen, X., Renzoni, E. A., Kennedy, L., Howat, S., Chen, Y., Pearson, J. D., Bou–Gharios, G., Dashwood, M. R., du Bois, R. M., Black, C. M., et al. (2007) · Matrix Biology · doi:10.1016/j.matbio.2007.06.003 · Cited by 116
Self-citationHolmes, A., Abraham, D. J., Chen, Y., Denton, C., Shi-wen, X., Black, C. M., & Leask, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305019200 · Cited by 115 · cited 3×
“In fibrotic fibroblasts isolated from the involved skin area of scleroderma patients, CCN2 is over-expressed independent of TGFβ and Smads but is dependent on BCE-1, Sp1 and endothelin-1 (Holmes et al. 2001, 2003; Chen et al. 2006; Shi-wen et al. 2007a).”
BackgroundSelf-citationNguyen, T. Q., Tarnow, L., Andersen, S., Hovind, P. H., Parving, H., Goldschmeding, R., & van Nieuwenhoven, F. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1670 · Cited by 114 · cited 1×
“End-stage renal disease (Nguyen et al. 2006)”
Urinary Connective Tissue Growth Factor Excretion in Patients With Type 1 Diabetes and Nephropathy
Gilbert, R. E., Akdeniz, A., Weitz, S., Usinger, W. R., Molineaux, C. J., Jones, S., Langham, R. G., & Jerums, G. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2632 · Cited by 108
Connective Tissue Growth Factor is a Biomarker and Mediator of Kidney Allograft Fibrosis
Cheng, O., Thuillier, R., Sampson, E. M., Schultz, G. S., Ruiz, P., Zhang, X., Yuen, P. S. T., & Mannon, R. B. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01493.x · Cited by 105 · cited 1×
“skin fibrosis in scleroderma (Dziadzio et al. 2005) Kidney allograft fibrosis ( Cheng et al 2006 ) liver fibrosis (Gressner et al. 2006) chronic viral hepatitis (Gressner et al. 2006) Fibrotic carcinoid tumors (Kidd et al 2007) diabetic retinopathy (Kuiper et al 2008) End-stage renal disease (Nguyen et al. 2006) myoca…”
BackgroundN-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma
Dziadzio, M., Usinger, W., Leask, A., Abraham, D., Black, C. M., Denton, C., & Stratton, R. (2005) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hci078 · Cited by 99 · cited 2×
“N-terminal CCN2 levels in plasma and dermal interstitial fluid correlated with severity of skin disease of scleroderma and (negatively) with disease duration (Dziadzio et al. 2005).”
BackgroundSelf-citationKoitabashi, N., Arai, M., Niwano, K., Watanabe, A., Endoh, M., Suguta, M., Yokoyama, T., Tada, H., Toyama, T., Adachi, H., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.02.011 · Cited by 97 · cited 2×
“myocardial fibrosis (Koitabashi et al. 2008) Connective tissue growth factor (CTGF, CCN2) gene regulation 91”
BackgroundUrinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report
Riser, B. L., Cortés, P., DeNichilo, M. O., Deshmukh, P. V., Chahal, P. S., Mohammed, A. K., Yee, J., & Kahkonen, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00130.x · Cited by 94 · cited 2×
“For example, urinary CCN2 levels appear at both stage nephropathy and appear to predict those patients who are destined for progressive glomerulosclerosis and end-stage renal disease (Riser et al. 2003).”
BackgroundEpithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis
Kantarcı, A., Black, S., Xydas, C., Murawel, P., Uchida, Y., Yucekal-Tuncer, B., Atilla, G., Emingil, G., Uzel, M., Lee, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2000 · Cited by 94 · cited 2×
“tissue fibroblasts, myofibroblasts, pericytes) and generally not in epithelial cells (Leask et al. 2001, 2003; Kantarci et al. 2006).”
BackgroundIto, Y., Goldschmeding, R., Bende, R. J., Claessen, N., CHAND, M. A., Kleij, L., Rabelink, T. J., Weening, J. J., & Aten, J. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123472 · Cited by 93
Chen, Y., Shiwen, X., Eastwood, M., Black, C. M., Denton, C. P., Leask, A., & Abraham, D. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21725 · Cited by 92 · cited 2×
“In fibrotic fibroblasts isolated from the involved skin area of scleroderma patients, CCN2 is over-expressed independent of TGFβ and Smads but is dependent on BCE-1, Sp1 and endothelin-1 (Holmes et al. 2001, 2003; Chen et al. 2006; Shi-wen et al. 2007a).”
BackgroundSelf-citationThe induction of CCN2 by TGFβ1 involves Ets-1
van Beek, J. P., Kennedy, L., Rockel, J. S., Bernier, S. M., & Leask, A. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1890 · Cited by 82 · cited 1×
“Recently, we have shown this motif to be a functional ETS binding element; Ets-1 is required for the ability of TGFβ to induce CCN2 expression. siRNA recognizing Ets-1 ablates the ability of TGFβ to induce CCN2 (van Beek et al. 2006; Fig.”
BackgroundSelf-citationDenton, C. P., Khan, K., Hoyles, R. K., Shiwen, X., Leoni, P., Chen, Y., Eastwood, M., & Abraham, D. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.171 · Cited by 79 · cited 1×
“Intriguingly, elective disruption of TβRII in mouse skin fibroblasts increases constitutive expression CTGF/CCN2 (Denton et al. 2009).”
BackgroundSelf-citationConnective Tissue Growth Factor Is Secreted through the Golgi and Is Degraded in the Endosome
Chen, Y., Segarini, P. R., Raoufi, F., Bradham, D. M., & Leask, A. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5364 · Cited by 76 · cited 2×
“In adult mammals, CCN2 exhibits a restricted expression, produced only by hepatic stellate cells (Paradis et al. 1999; Chen et al. 2001) and kidney mesangial cells (Ito et al.”
BackgroundSelf-citationRegulation of connective tissue growth factor expression by prostaglandin E2
Ricupero, D. A., Rishikof, D. C., Kuang, P.-P., Poliks, C. F., & Goldstein, R. H. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.6.l1165 · Cited by 69 · cited 1×
“Moreover, prostaglandins [PGE(2)] and prostacyclins (such as the synthetic prostacyclin Iloprost) can antagonize CCN2 expression, including in scleroderma fibroblasts (Ricupero et al. 1999; Stratton et al. 2001, 2002).”
BackgroundCTGF, intestinal stellate cells and carcinoid fibrogenesis
Kidd, M. S. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i39.5208 · Cited by 69 · cited 1×
“skin fibrosis in scleroderma (Dziadzio et al. 2005) Kidney allograft fibrosis (Cheng et al 2006) liver fibrosis (Gressner et al. 2006) chronic viral hepatitis (Gressner et al. 2006) Fibrotic carcinoid tumors ( Kidd et al 2007 ) diabetic retinopathy (Kuiper et al 2008) End-stage renal disease (Nguyen et al. 2006) myoca…”
BackgroundThomson, S. E., McLennan, S. V., Kirwan, P. D., Heffernan, S. J., Hennessy, A., Yue, D. K., & Twigg, S. M. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.07.001 · Cited by 65 · cited 2×
“In addition, glomerular basement membrane thickness correlates with tubular and total CCN2 levels (Thomson et al. 2008) In particular, studies using an enzyme-linked immunosorbent assay (ELISA) to examining the appearance of amino-terminal fragments of CCN2 appear especially promising as potential diagnostic tools to…”
BackgroundPhanish, M. K., Wahab, N. A., Hendry, B. M., & Dockrell, M. E. C. (2005) · Nephron Experimental Nephrology · doi:10.1159/000085445 · Cited by 62 · cited 2×
“Biomarker”
BackgroundThe gene expression profile induced by Wnt 3a in NIH 3T3 fibroblasts
Chen, S., McLean, S., Carter, D. E., & Leask, A. (2007) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-007-0015-x · Cited by 58 · cited 1×
“Finally, Wnt3a induces CCN2 through a β-catenin-dependent mechanism, although the promoter sequences mediating this action are unknown, they reside within in the first 805 base pairs of the CCN2 proximal promoter (Luo et al. 2004; Chen et al. 2007).”
BackgroundSelf-citationKondo, S., Kubota, S., Mukudai, Y., Moritani, N. H., Nishida, T., Matsushita, H., Matsumoto, S., Sugahara, T., & Takigawa, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209129 · Cited by 57
Kubota, S., Kondo, S., Eguchi, T., Hattori, T., Nakanishi, T., Pomerantz, R. J., & Takigawa, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203835 · Cited by 52 · cited 1×
“The 3′-untranslated region (3′-UTR) has a suppressive effect on CCN2 gene expression via a minimal RNA element in the 3′-UTR, which acts as a cis-acting element of structureanchored repression (CAESAR) (Kubota et al. 2000).”
BackgroundConnective tissue growth factor promoter activity in normal and wounded skin
Kapoor, M., Liu, S., Huh, K., Parapuram, S. K., Kennedy, L., & Leask, A. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-3 · Cited by 49 · cited 2×
“Although CCN2 is not normally expressed by other mesenchymal cells, it is rapidly induced during the tissue repair process, for example upon injury (Igarashi et al. 1993; Kapoor et al. 2008 ).”
BackgroundSelf-citationRegulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells
Leask, A., Chen, S., Pala, D., & Brigstock, D. R. (2008) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-008-0029-z · Cited by 33 · cited 2×
“As discussed above, inhibitors of TGFβ or endothelin receptors may be used to reduce CCN2 expression in activated hepatic stellate cells or scleroderma fibroblasts, respectively (Leask et al. 2008; Shi-wen et al. 2007a).”
BackgroundSelf-citationQi, W., Chen, X., Twigg, S. M., ZHANG, Y., Gilbert, R. E., Kelly, D. J., & Pollock, C. A. (2007) · Nephrology · doi:10.1111/j.1440-1797.2007.00788.x · Cited by 21 · cited 1×
“CCN2 may exert its stimulating effect on TGFβ signaling by decreasing Smad7 availability and increasing Smad2 (Qi et al. 2007).”
BackgroundThe 5′ untranslated regions (UTRs) of CCN1, CCN2, and CCN4 exhibit cryptic promoter activity
Huang, B., Dornbach, L. M., & Lyons, K. M. (2007) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-007-0003-1 · Cited by 12
Ceramide inhibits CCN2 expression in fibroblasts
Kennedy, L., Parapuram, S. K., Greenspoon, J., & Leask, A. (2008) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-008-0024-4 · Cited by 4 · cited 1×
“Finally, it has been shown recently that the addition of the lipid second messenger C2ceramide can also reduce TGFβ-induced CCN2 expression in human foreskin fibroblasts (Kennedy et al. 2008).”
BackgroundSelf-citation
Cited by
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
Jun, J.-I., & Lau, L. F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3599 · Cited by 568
Cutaneous wound healing: recruiting developmental pathways for regeneration
Bielefeld, K. A., Amini-Nik, S., & Alman, B. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1152-9 · Cited by 483
Matricellular Proteins in Cardiac Adaptation and Disease
Frangogiannis, N. G. (2012) · Physiological Reviews · doi:10.1152/physrev.00008.2011 · Cited by 445
Hinz, B. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.07.009 · Cited by 424
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., Brenner, M., Guo, G., Zhang, W., Oliver, N., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-4 · Cited by 278
Metadata
- Authors
- Leask, A., Parapuram, S. K., Shi‐wen, X., & Abraham, D. J.
- Venue
- Journal of Cell Communication and Signaling
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 3
- Issue
- 2
- Pages
- 89-94
- ISSN
- 1873-9601 (ISSN-L)
- 1873-961X
- OpenAlex
- W2135861680
- Cited by
- 176
- References
- 53
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.